This topic contains a solution. Click here to go to the answer

Author Question: Which evidence-based client-level factor affects nonadherence? 1. Management of instructions by ... (Read 116 times)

BrownTown3

  • Hero Member
  • *****
  • Posts: 564
Which evidence-based client-level factor affects nonadherence?
 
  1. Management of instructions by the health care provider
  2. Simplification of the regimen
  3. Identification of the client's social support network
  4. Belief that the treatment will be effective

Question 2

A nurse who works at a nursing home notices that a client's hearing has diminished significantly over the past couple of days. The client has been receiving gentamicin IV for an infection. Which action by the nurse is the most appropriate?
 
  1. Continue gentamicin IV and check the peak level in a week.
  2. Suggest checking the client's peak gentamicin level and immediately report the loss in hearing in the chart and to the health care provider.
  3. Tell the client that she is going to need a hearing aid.
  4. Continue gentamicin IV and suggest adding vancomycin IV to improve the ototoxicity.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

macagn

  • Sr. Member
  • ****
  • Posts: 345
Answer to Question 1

Correct Answer: 4
Rationale 1: The management of instructions is a health care provider-level factor, not a client-level factor.
Rationale 2: Making the regimen less complex is a health care provider-level factor, not a client-level factor.
Rationale 3: The social support network is a separate factor, not a client-level factor.
Rationale 4: Belief that the treatment will be effective is a client-level factor likely to improve adherence.
Global Rationale: Belief that the treatment will be effective is a client-level factor likely to improve adherence. The management of instructions is a health care provider-level factor, not a client-level factor. Making the regimen less complex is a health care provider-level factor, not a client-level factor. The social support network is a separate factor, not a client-level factor.

Answer to Question 2

Correct Answer: 2
Rationale 1: Gentamicin is a narrow-therapeutic-window drug, and levels should be assessed sooner.
Rationale 2: Gentamicin is a narrow-therapeutic-window drug that can cause ototoxicity and nephrotoxicity. A peak level can help determine the likelihood that it is the drug causing the hearing loss.
Rationale 3: It would be inappropriate to notice a sudden change in hearing and not consider that it might be drug related. Also, all adverse effects should be documented..
Rationale 4: Both vancomycin and gentamicin have the ability to cause nephrotoxicity and ototoxicity. Giving both together would not help the ototoxicity.
Global Rationale: Gentamicin is a narrow-therapeutic-window drug that can cause ototoxicity and nephrotoxicity. A peak level can help determine the likelihood that it is the drug causing the hearing loss. Gentamicin is a narrow-therapeutic-window drug, and levels should be assessed sooner. It would be inappropriate to notice a sudden change in hearing and not consider that it might be drug related. Also, all adverse effects should be documented. Both vancomycin and gentamicin have the ability to cause nephrotoxicity and ototoxicity. Giving both together would not help the ototoxicity.




macagn

  • Sr. Member
  • ****
  • Posts: 345

 

Did you know?

Patients who have been on total parenteral nutrition for more than a few days may need to have foods gradually reintroduced to give the digestive tract time to start working again.

Did you know?

A strange skin disease referred to as Morgellons has occurred in the southern United States and in California. Symptoms include slowly healing sores, joint pain, persistent fatigue, and a sensation of things crawling through the skin. Another symptom is strange-looking, threadlike extrusions coming out of the skin.

Did you know?

Signs and symptoms of a drug overdose include losing consciousness, fever or sweating, breathing problems, abnormal pulse, and changes in skin color.

Did you know?

Patients who have undergone chemotherapy for the treatment of cancer often complain of a lack of mental focus; memory loss; and a general diminution in abilities such as multitasking, attention span, and general mental agility.

Did you know?

The FDA recognizes 118 routes of administration.

For a complete list of videos, visit our video library